Ravin Ratan
Assistant Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (2)
Supplement Table 1: Histologic Make-up of common sarcomas Supplement Table 2: List of common alterations among URS population by frequency Supplement Table 3: Sarcomas experiencing without clinical benefit (e.g. SD for
Year:
2025
Purpose: Developing new therapeutics for any of the more than 100 sarcoma subtypes presents a challenge. After progression from standard therapies, patients with sarcoma may be referred for enrollment in early-phase trials. This study aimed to investigate whether enrollment in biomarker-matched early-phase clinical trials leads to better outcomes for patients with advanced sarcoma. Experimental Design: In this retrospective analysis, investigational treatment characteristics and longitudinal survival outcomes were analyzed in patients with biopsy-confirmed sarcoma enrolled in early-phase trials at MD Anderson Cancer Center from May 2006 to July 2021. Results: Five hundred eighty-seven patients were included [405 soft tissue, 122 bone, 60 gastrointestinal stromal tumor (GIST); median of three prior lines of therapy]. Most common subtypes were leiomyosarcoma (17.2%), liposarcoma (14.0%), and GIST (10.2%). Molecular testing was available for 511 patients (87.1%); 221 patients (37.6%) were treated in matched trials. Overall response rate was 13.1% matched compared with 4.9% in unmatched ( P P P P Conclusions: Enrollment in biomarker-matched early-phase trials is associated with improved outcomes in heavily pretreated patients with metastatic sarcoma. Molecular testing of tumors from patients with advanced sarcoma and enrollment in matched trials is a reasonable therapeutic strategy.
Year:
2024
Collaborators (23)
Janos Roszik
The University of Texas MD Anderson Cancer Center
Christina Lynn Roland
The University of Texas MD Anderson Cancer Center
Neeta Somaiah
Professor and Chair
The University of Texas MD Anderson Cancer Center
Richard Gorlick
The University of Texas MD Anderson Cancer Center
Aung Naing
The University of Texas MD Anderson Cancer Center
Vivek Subbiah
Professor of Medicine and of Pediatrics
Stanford University
Apostolia M. Tsimberidou
Professor
The University of Texas MD Anderson Cancer Center
Shreyaskumar Patel
Professor
The University of Texas MD Anderson Cancer Center
Douglas J. Harrison
-
Justin Moyers
-
Anthony P. Conley
Associate Professor
The University of Texas MD Anderson Cancer Center
Sarina Piha-Paul
Professor
The University of Texas MD Anderson Cancer Center
Siqing Fu
Professor
The University of Texas MD Anderson Cancer Center
David S. Hong
The University of Texas MD Anderson Cancer Center
J Andrew Livingston
Associate Professor
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam
The University of Texas MD Anderson Cancer Center
VINOD RAVI
Associate Professor
The University of Texas MD Anderson Cancer Center
Valerae Lewis
Professor and Chair
MD Anderson Cancer Center
Cynthia Herzog
Professor
MD Anderson Cancer Center
Alexander Lazar
Professor
The University of Texas MD Anderson Cancer Center
Wei-Lien Wang
Associate Professor
The University of Texas MD Anderson Cancer Center
Timothy Yap
The University of Texas MD Anderson Cancer Center
Shubham Pant
Professor
The University of Texas MD Anderson Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.